PCOS Has Been Renamed PMOS — Here's What That Means For You
Written by Jessica Diakoumakos, Naturopath (BHSc Naturopathy) · Emba Wellness, Melbourne
On 12 May 2026, polycystic ovary syndrome (PCOS) was officially renamed polyendocrine metabolic ovarian syndrome (PMOS) in a landmark global consensus paper published in The Lancet. The name change — led by Professor Helena Teede of Monash University in Melbourne and supported by 56 leading academic, clinical, and patient organisations worldwide — follows more than a decade of research, advocacy, and over 22,000 survey responses from patients and clinicians across the globe. The new name reflects what researchers and clinicians have known for years: that this condition is not primarily about ovarian cysts, but is instead a complex, multisystem hormonal and metabolic disorder. This post explains what changed, why it matters, and what it means for you if you have — or suspect you have — this condition.
What Does PMOS Stand For — And Why?
Polyendocrine Metabolic Ovarian Syndrome.Each word was chosen deliberately:Polyendocrine — recognises that the condition involves multiple interacting hormonal disturbances, not a single hormonal abnormality. Insulin, androgens, LH, and neuroendocrine hormones all play a role. This is not a condition of one hormone — it is a condition of how multiple hormonal systems interact with each other.Metabolic — acknowledges the inherent metabolic nature of the condition, including insulin resistance, dyslipidaemia, cardiovascular risk, and metabolic syndrome risk. These are not side effects of PMOS — they are core features of it.Ovarian — maintains reference to the ovaries, which remain central to the condition's reproductive and hormonal features, without overemphasising ovarian morphology or implying pathological cysts.Syndrome — preserved because the condition is defined by a cluster of features rather than a single cause or abnormality.
Why This Matters Clinically — And Why I've Been Saying This For Years
If you've read my other posts on this condition — particularly my complete guide to PCOS/PMOS — you'll recognise that everything the new name is trying to communicate is already central to how I approach this condition in clinical practice.I have never treated PMOS as a gynaecological condition. I treat it as a metabolic and endocrine condition that happens to have ovarian and reproductive consequences.I have always tested fasting insulin and HOMA-IR, not just reproductive hormones — because insulin resistance is present in up to 70–80% of women with this condition and is one of its primary drivers.I have always discussed the mental health burden of this condition — the anxiety, depression, body image distress, and eating disorder risk — because ignoring psychological health in PMOS management is a significant clinical failure.And I have always pushed back against the idea that the oral contraceptive pill is a "treatment" for this condition. It suppresses symptoms. It does not address the underlying metabolic and hormonal dysfunction.The new name validates every aspect of this approach. And more importantly, it means that when women walk into a GP's office with a PMOS diagnosis in the future, the name itself will prompt a broader, more appropriate clinical conversation.
What the Name Change Means For You
If you have already been diagnosed with PCOS: Your diagnosis is still valid. The condition hasn't changed — only its name has. Everything you know about your condition, your symptoms, and your treatment applies equally to PMOS. Over the next three years, you'll likely see both names used interchangeably as the transition happens across clinical guidelines, medical records, and health systems.
If you've been dismissed or undertreated: The name change is specifically designed to address this. By removing the focus on ovarian cysts and replacing it with a name that emphasises hormonal and metabolic complexity, the new name should prompt more thorough diagnostic workups and broader treatment conversations. If your PMOS has never been assessed for insulin resistance, cardiovascular risk, or mental health — that conversation is now even more overdue.
If you've been told "your ultrasound was normal so you don't have PCOS": This is one of the most important implications of the name change. The old name's emphasis on "polycystic" ovaries led to significant under-diagnosis when ultrasound findings were absent or inconclusive. The Rotterdam criteria — now further supported by the 2023 International Guidelines — require only two of three features for diagnosis. Ultrasound findings are just one of those features.
If you're in the diagnostic process: The transition period means you may encounter both PCOS and PMOS in your medical records and clinical conversations for the next few years. They refer to the same condition. Don't let the terminology difference cause confusion about your care.
The Melbourne Connection
It's worth noting with genuine pride that this historic name change was led by Professor Helena Teede at Monash University in Melbourne — the same institution whose research underpins the international guidelines I reference in all my clinical PCOS/PMOS work.
Melbourne is at the forefront of global women's health research, and this name change is a reflection of that. The fact that the most rigorous disease-renaming process in medical history was led from our city, and has now changed how 170 million women worldwide will have their condition described, is remarkable.
“The name change from PCOS to PMOS is the most validating moment I have experienced as a naturopath working in this space. It confirms what we have always known clinically — that this is a metabolic and endocrine condition first, and an ovarian condition second. I hope this changes the conversations women have with every practitioner they see.”
What Emba Wellness Is Doing
I am updating all of my PMOS content to reflect the new name over the coming weeks. In the meantime, both PCOS and PMOS will be used throughout my blog to ensure women searching under either term can find the information they need.
My clinical approach to this condition has not changed — because the name change confirms rather than contradicts the way I have always understood and treated it. What I hope will change is the standard of care these women receive from the broader medical system.
Frequently Asked Questions
-
PMOS stands for polyendocrine metabolic ovarian syndrome. It is the new official name for the condition previously known as polycystic ovary syndrome (PCOS), renamed in a landmark global consensus published in The Lancet on 12 May 2026. The condition itself has not changed — only its name has.
-
The old name was found to be inaccurate and harmful — implying pathological ovarian cysts that don't actually exist in the condition, obscuring its true metabolic and endocrine nature, and contributing to delayed diagnosis, fragmented care, and stigma. The new name more accurately reflects the condition's hormonal and metabolic complexity.
-
Yes. PMOS and PCOS refer to the same condition. The name change is official as of 12 May 2026, following a decade-long global consensus process. During a three-year transition period, both names will be used in clinical and patient settings.
-
Not immediately. The transition from PCOS to PMOS will happen gradually over approximately three years as clinical guidelines, medical education, and disease classification systems are updated worldwide. Your existing diagnosis remains valid.
-
The clinical approach to PMOS does not change as a result of the name change — the same diagnostic criteria and treatment principles apply. However, the name change is intended to prompt broader, more accurate clinical conversations that address the full metabolic and endocrine picture rather than focusing narrowly on ovarian morphology.
-
The name change was led by Professor Helena Teede of Monash University in Melbourne, Australia, alongside international co-leads and representatives from 56 patient and professional organisations worldwide. It was published in The Lancet on 12 May 2026.
-
Polyendocrine refers to the involvement of multiple interacting hormonal systems in the condition — including insulin, androgens, LH, and neuroendocrine hormones. It signals that PMOS is not a condition of one hormone but of how multiple hormonal systems interact and dysregulate together.
Want to Understand Your PMOS More Deeply?
If you've been diagnosed with PCOS or PMOS — or suspect you might have it — and want to understand what's actually driving your symptoms, I'd love to work with you.
At Emba Wellness, I take a comprehensive, root-cause approach to PMOS/PCOS — looking at the full hormonal and metabolic picture, not just reproductive markers.
I offer 1:1 consults in Melbourne and via telehealth across Australia.
Further Reading on PMOS/PCOS at Emba Wellness
About the Author
Jessica Diakoumakos | BHSc Naturopathy & BHSc Psychology Clinical Naturopath & Founder, Emba Wellness — Melbourne, Victoria, Australia
Jess is a Melbourne-based clinical naturopath and founder of Emba Wellness.
She specialises in:
Gut health — IBS, SIBO, bloating, microbiome repair, leaky gut
Hormonal health — PCOS, endometriosis, PMS, perimenopause, post-pill recovery
Functional pathology — interpreting blood tests through a root-cause lens
Energy & thyroid — Hashimoto's, fatigue, burnout, adrenal dysregulation
Immune health — autoimmune conditions, chronic inflammation, immune dysregulation
Her approach is evidence-based and deeply personal. Having managed her own Hashimoto's thyroiditis through naturopathic medicine, Jess understands first-hand what it feels like to be dismissed by conventional medicine — and what it feels like to finally get answers.
Emba Wellness offers naturopathy consultations via Telehealth, across Australia.
-
Teede, H. J., Piltonen, T. T., Dokras, A., Morman, R., & Global Name Change Consortium. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. https://doi.org/10.1016/S0140-6736(26)00717-8
Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology & Metabolism, 108(10), 2447–2469. https://doi.org/10.1210/clinem/dgad463
All content published on the Emba Wellness blog is written by Jessica Diakoumakos and is intended for educational purposes only. It does not constitute medical advice. Please consult a qualified health practitioner before making changes to your health care.
